Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats

An orally bioavailable small molecule inhibitor of plasminogen activator inhibitor-1 (PAI-1) is currently being clinically assessed as a novel antithrombotic agent. Although PAI-1 is known to serve a key role in the pathogenesis of metabolic syndrome (MetS) including nonalcoholic steatohepatitis (NA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Med Rep
Main Authors: Noguchi, Ryuichi, Kaji, Kosuke, Namisaki, Tadashi, Moriya, Kei, Kawaratani, Hideto, Kitade, Mitsuteru, Takaya, Hiroaki, Aihara, Yosuke, Douhara, Akitoshi, Asada, Kiyoshi, Nishimura, Norihisa, Miyata, Toshio, Yoshiji, Hitoshi
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2020
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7453658/
https://ncbi.nlm.nih.gov/pubmed/32945412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2020.11360
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados